Aim To determine an influence of alpha-lipoic acid to reduction of body weight and regulation of total cholesterol concentration, triglycerides and glucose serum levels in obese patients with diabetes mellitus type 2. Methods A prospective study includes two groups of obese patients with diabetes mellitus and signs of peripheral polyneuropathia: examined group (30 patients; 15 females and 15 males), and control group (30 patients; 12 females and 18 males). All were treated with metformin (850-1700 mg/day). Examined patients were additionally treated with alpha-lipoic acid 600 mg/day during 20 weeks. Body mass index and concentrations of total cholesterol, triglycerides and glucose in serum were compared before and after the treatment. Results The group treated with 600 mg alpha-lipoic acid lost significantly more weight, and had lower triglyceride level than the control group. There were no significant differences in total cholesterol and glucose serum levels between the groups. Conclusion Alpha-lipoic acid of 600 mg/day treatment have influenced weight and triglycerides loss in obese patients with diabetes mellitus type 2. It should be considered as an important additive therapy in obese patients with diabetes mellitus type 2.
Shin J, Lee J, Lim S, Ha H, Kwon H, Park Y, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 2013. p. 334–43.
2.
Porasuphatana S, Suddee S, Nartnampong A, Konsil J, Harnwong B, Santaweesuk A. Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study. Asia Pac J Clin Nutr. 2012. p. 12–21.
3.
Choi S, Ginsberg H. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab. 2011. p. 353–63.
4.
Seo E, Ha A, Kim W. Alpha-Lipoic acid reduced weight gain and improved the lipid profile in rats fed with high fat diet. Nutr Res Pract. 2012. p. 195–200.
5.
Gupta S, Gambhir J, Kalra O, Gautam A, Shukla K, Mehndiratta M, et al. Association of biomarkers of inflammation and oxidative stress with the risk of chronic kidney disease in Type 2 diabetes mellitus in North Indian population. J Diabetes Complications. 2013. p. 548–52.
6.
Morakinyoao A, Fo, Adegoke O. Effects of alpha lipoic acid on blood lipids, renal indices, antioxidant enzymes, insulin and glucose level in streptozotocin-diabetic rats. Biology and Medicine. 2013. p. 26–33.
7.
Kandeil M, Amin K, Hassanin K, Ali K, Mohammed E. Role of lipoic acid on insulin resistance and leptin in experimentally diabetic rats. J Diabetes Complications. 2011. p. 31–8.
8.
Song K, Lee W, Koh J, Kim H, Youn J, Park H, et al. Alpha-Lipoic acid prevents diabetes mellitus in diabetes-prone obese rats. Biochem Biophys Res Commun. 2005. p. 197–202.
9.
Koh E, Lee W, Lee S, Kim E, Cho E, Jeong E, et al. Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med. 2011. p. 85–8.
10.
Carrier B, Rideout T. Anti-Obesity and Lipid-Lowering Properties of Alpha-Lipoic Acid. J Hum Nutr Food Sci. 2013. p. 1002.
11.
Ratliff J, Palmese L, Reutenauer E, Tek C. An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. Clin Schizophr Relat Psychoses. 2013. p. 1–13.
12.
Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012. p. 465–71.
13.
Xu Q, Pan J, Yu J, Liu X, Liu L, Zuo X, et al. Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Res Clin Pract. 2013. p. 99–105.
14.
Hahm J, Kim B, Kim K. Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. J Diabetes Complications. 2004. p. 79–85.
15.
Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol. 2004. p. 173–89.
16.
Gębka A, Serkies-Minuth E, Raczyńska D. Effect of the administration of alpha-lipoic acid on contrast sensitivity in patients with type 1 and type 2 diabetes. Mediators Inflamm. 2014. p. 131538.
17.
Lee W, Kim A, Kim K, Park Y, Park J, Kim K, et al. Alpha-lipoic acid attenuates atherosclerotic lesions and inhibits proliferation of vascular smooth muscle cells through targeting of the Ras/MEK/ERK signaling pathway. Mol Biol Rep. 2012. p. 6857–66.
18.
Sun Y, Dong Y, Fan R, Zhai L, Bai Y, Jia L. Effect of alpha lipoic acid supplementation on serum lipids and antioxidative ability in patients with agerelated macular degeneration. Ann Nutr Metab. 2012. p. 293–7.
19.
Cicek M, Yıldırır A, Okyay K, Yazici A, Aydinalp A, Kanyilmaz S, et al. Use of alpha-lipoic acid in prevention of contrast-induced nephropathy in diabetic patients. Ren Fail. 2013. p. 748–53.
20.
Chen W, Kang C, Wang S, Lee H. Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Diabetologia. 2012. p. 1824–35.
21.
Zhang Y, Han P, Wu N, He B, Lu Y, Li S, et al. Amelioration of lipid abnormalities by alpha-lipoic acid through antioxidative and antiinflammatory effects. Obesity (Silver Spring). 2011. p. 1647–53.
22.
Napolitano A, Miller S, Nicholls A, Baker D, Van Horn S, Thomas E, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014. p. 100778.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
